Abstract
Previous studies reveal that fibroblast growth factor 21 (FGF21) sensitizes insulin to achieve a synergy in regulating glucose metabolism. Here, we report that insulin sensitizes FGF21 in regulating both glucose and lipid metabolisms. db/db diabetic mice were subcutaneously administrated once a day for 6 weeks. Effective dose of insulin (1 U) could control blood glucose level of the db/db mice for maximum of 2 h, increased the body weight of the db/db mice and did not improve serum lipid parameters. In contrast, effective dose of FGF21 (0.5 mg/kg) could maintain blood glucose of the db/db mice at normal level for at least 24 h, repressed the weight gain of the mice and significantly improved lipid parameters. Ineffective doses of FGF21 (0.125 mg/kg) and insulin had no effect on blood glucose level of the db/db mice after 24 h administration, body weight or lipid parameters. However, combination of the two ineffective doses could maintain blood glucose level of the db/db mice for at least 24 h, suppressed weight gain and significantly improved lipid parameters. These results suggest that insulin sensitizes FGF21 in regulating both glucose and lipid metabolism. The results aimed to study the molecular basis of FGF21 sensitization indicates that combination of the two ineffective doses increased the mRNA expression of glut1, glut4, β-Klotho, sirt1, pgc-1α, ucp-1 and AKT phosphorylation, decreased fasn. The results demonstrate that insulin sensitizes FGF21 through elevating the phosphorylation of common gene Akt and amplifying FGF21 downstream signaling, including increasing expression of glut1 sirt1, pgc-1α, ucp-1, and decreasing fasn expression. In summary, we reports herein for the first time that insulin sensitizes FGF21 to achieve a synergy in regulating glucose and lipid metabolism. Along with previous studies, we conclude that the synergistic effect between FGF21 and insulin is realized through mutual sensitization.
Similar content being viewed by others
Abbreviations
- FGF21:
-
Fibroblast growth factor 21
- AKT:
-
Protein kinase B
- glut1/4 :
-
Glucose transport1/4
- fasn :
-
Fatty acid synthase
- sirt1:
-
Silent mating type information regulation 2 homolog 1
- pgc-1a:
-
Peroxisome proliferator-activated receptor gamma coactivator-1α
- ucp-1:
-
Uncoupling protein -1
- hASC:
-
Human adipose stem cell derived cells
- IR:
-
Insulin resistant
- GHb:
-
Glycosylated hemoglobin or glycated hemoglobin
- TG:
-
Triacylglycerol
- TC:
-
Total Cholesterol
- LDL:
-
Low-Density Lipoprotein
- HDL:
-
High density lipoprotein
- OGTT:
-
Oral glucose tolerance test
- BCA:
-
Bicinchonini\c acid
- DTT:
-
Dithiothreitol
- g6pase :
-
Glucose-6-phosphatase
- pepck :
-
Phosphoenolpyruvate carboxykinase
- FGFR:
-
Fibroblast growth factor receptor
References
A.R. Saltiel, C.R. Kahn, Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414(6865), 799–806 (2001)
A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J. Galbreath, G.E. Sandusky et al., FGF21 as a novel metabolic regulator. J. Clin. Invest. 115(6), 1627–1635 (2005)
A. Kharitonenkov, J.D. Dunbar, H.A. Bina, S. Bright, J.S. Moyers, C. Zhang, L. Ding et al., FGF21/FGF21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 215(1), 1–7 (2008)
A. Kharitonenkov, A.B. Shanafelt, Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 22(1), 37–44 (2008)
Y. Izumiya, H.A. Bina, N. Ouchi, Y. Akasaki, A. Kharitonenkov, K. Walsh, FGF21 is an Akt-regulated myokine. FEBS Lett. 582(27), 3805–3810 (2008)
A.C. Adams, T. Coskun, A.R. Rovira, M.A. Schneider, D.W. Raches, R. Micanovic et al., Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS ONE 7(5), E38438 (2012)
T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, Y. Chen et al., Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149(12), 6018–6027 (2008)
M.M. Véniant, C. Hale, J. Helmering, M.M. Chen, S. Stanislaus, J. Busby et al., FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice. PLoS One 7(7), E40164 (2012)
J. Xu, D.J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits, S. Vonderfecht et al., Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58(1), 250–259 (2009)
B. Angelin, T.E. Larsson, M. Rudling, Circulating fibroblast growth factors as metabolic regulators-a critical appraisal. Cell Metab. 16(6), 693–705 (2012)
A. Kharitonenkov, J.M. Beals, R. Micanovic, B.A. Strifler, R. Rathnachalam, V.J. Wroblewski, S. Li et al., Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One 8(3), E58575 (2013)
Y.C. Woo, A. Xu, Y. Wang, K.S. Lam, Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol. (Oxf) 78(4), 489–496 (2013)
J. Huang, T. Ishino, G. Chen, P. Rolzin, T.F. Osothprarop, K. Retting, L. Li et al., Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J. Pharmacol. Exp. Ther. 346(2), 270–280 (2013)
D.V. Lee, D. Li, Q. Yan, Y. Zhu, B. Goodwin, R. Calle, M.B. Brenner et al., Fibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes. PLoS One 9(11), E111767 (2014)
G.R. Gandhi, A. Stalin, K. Balakrishna, S. Ignacimuthu, M.G. Paulraj, R. Vishal, Insulin sensitization via partial agonism of PPARγ and glucose uptake through translocation and activation of GLUT4 in PI3 K/p-Akt signaling pathway by embelin in type 2 diabetic rats. Biochim. Biophys. Acta 1830(1), 2243–2255 (2013)
S.E. Kahn, M.E. Cooper, Prato. S. Del, Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383(9922), 1068–1083 (2014)
S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters et al., Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58(3), 429–442 (2015)
A.J. Garber, M.J. Abrahamson, J.I. Barzilay, L. Blonde, Z.T. Bloomgarden, M.A. Bush et al., American Association of Clinical Endocrinologists, AACE comprehensive diabetes management algorithm. Endocr Pract. 19(2), 327–336 (2013)
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, A.Y. Cheng, Canadian Diabetes Association, clinical practice guidelines for the prevention and management of diabetes in Canada: methods. Can. J. Diabetes 37, S1–S3 (2013)
R. Chawla, P. Thakur, A. Chowdhry, S. Jaiswal, A. Sharma, R. Goel, J. Sharma et al., Evidence based herbal drug standardization approach in coping with challenges of holistic management of diabetes: a dreadful lifestyle disorder of 21st century. J. Diabetes Metab. Disord. 12(1), 35 (2013)
B. Emanuelli, S.G. Vienberg, G. Smyth, C. Cheng, K.I. Stanford, M. Arumugam et al., Interplay between FGF21 and insulin action in the liver regulates metabolism. J. Clin. Invest. 125(1), 458 (2015)
J.P. Camporez, F.R. Jornayvaz, M.C. Petersen, D. Pesta, B.A. Guigni, J. Serr, D. Zhang et al., Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154(9), 3099–3109 (2013)
P. Raskin, R.A. Guthrie, L. Leiter, A. Riis, L. Jovanovic, Use of insulin aspart, a Fast-acting inulin analog, as the mealtime insulin in the management of patients with Type1 diabetes. Diabetes Care 23(5), 583–588 (2000)
X. Ge, C. Chen, X. Hui, Y. Wang, K.S. Lam, A. Xu, Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J. Biol. Chem. 286(40), 34533–34541 (2011)
P. Iglesias, R. Selgas, S. Romero, J.J. Díez, Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur. J. Endocrinol. 167(3), 301–309 (2012)
J. Xu, S. Stanislaus, N. Chinookoswong, Y.Y. Lau, T. Hager, J. Patel, H. Ge et al., Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297(5), E1105–E1114 (2009)
M.M. Véniant, C. Hale, J. Helmering, M.M. Chen, S. Stanislaus, J. Busby, S. Vonderfecht et al., FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One 7(7), E40164 (2012)
M.M. Véniant, R. Komorowski, P. Chen, S. Stanislaus, K. Winters, T. Hager, L. Zhou et al., Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153(9), 4192–4203 (2012)
J.J. Liu, J.P. Foo, S. Liu, S.C. Lim, The role of fibroblast growth factor 21 in diabetes and its complications: a review from clinical perspective. Diabetes Res. Clin. Pract. 108(3), 382–389 (2015)
Y. Zhang, T. Lei, J.F. Huang, S.B. Wang, L.L. Zhou, Z.Q. Yang, X.D. Chen, The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol. Cell. Endocrinol. 342(1–2), 41–47 (2011)
M.D. Chau, J. Gao, Q. Yang, Z. Wu, J. Gromada, Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc. Natl. Acad. Sci. USA 107(28), 12553–12558 (2010)
H. Jiao, P. Arner, S.L. Dickson, H. Vidal, N. Mejhert, C. Henegar et al., Genetic association and gene expression analysis identify FGFR1 as a new susceptibility gene for human obesity. J. Clin. Endocrinol. Metab. 96(6), E962–E966 (2011)
J. Yie, R. Hecht, J. Patel, J. Stevens, W. Wang, N. Hawkins et al., FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 583(1), 19–24 (2009)
W. Wente, A.M. Efanov, M. Brenner, A. Kharitonenkov, A. Köster, G.E. Sandusky et al., Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55(9), 2470–2478 (2006)
K. Tomiyama, R. Maeda, I. Urakawa, Y. Yamazaki, T. Tanaka, S. Ito et al., Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc. Natl. Acad. Sci. USA 107(4), 1666–1671 (2010)
S. Ito, S. Kinoshita, N. Shiraishi, S. Nakagawa, S. Sekine, T. Fujimori, Y.I. Nabeshima, Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech. Dev. 98(1–2), 115–119 (2000)
F.M. Fisher, J.L. Estall, A.C. Adams, P.J. Antonellis, H.A. Bina, J.S. Flier et al., Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152(8), 2996–3004 (2011)
F.M. Fisher, P.C. Chui, P.J. Antonellis, H.A. Bina, A. Kharitonenkov, J.S. Flier, E. Maratos-Flier, Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59(11), 2781–2789 (2010)
C. Yang, C. Jin, X. Li, F. Wang, W.L. McKeehan, Y. Luo, Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7(3), E33870 (2012)
Y. Ogawa, H. Kurosu, M. Yamamoto, A. Nandi, K.P. Rosenblatt, R. Goetz et al., BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA 104(18), 7432–7437 (2007)
M. Suzuki, Y. Uehara, K. Motomura-Matsuzaka, J. Oki, Y. Koyama, M. Kimura et al., betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22(4), 1006–1014 (2008)
M. Yang, L. Zhang, C. Wang, H. Liu, G. Boden, G. Yang, L. Li, Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS One 7(11), E48392 (2012)
P. Xu, Y. Zhang, W. Wang, Q. Yuan, Z. Liu, L.M. Rasoul et al., Long-Term Administration of Fibroblast Growth Factor 21 Prevents Chemically-Induced Hepatocarcinogenesis in Mice. Dig. Dis. Sci. 60(10), 3032–3043 (2015)
Y. Gao, M. Zhang, T. Wu, M. Xu, H. Cai, Z. Zhang, Effects of D-Pinitol on Insulin Resistance through the PI3 K/Akt Signaling Pathway in Type 2 Diabetes Mellitus Rats. J. Agric. Food Chem. 63(26), 6019–6026 (2015)
A. He, X. Liu, L. Liu, Y. Chang, F. Fang, How many signals impinge on GLUT4 activation by insulin? Cell. Signal. 19(1), 1–7 (2007)
J.S. Moyers, T.L. Shiyanova, F. Mehrbod, J.D. Dunbar, T.W. Noblitt, K.A. Otto et al., Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J. Cell. Physiol. 210(1), 1–6 (2007)
G. Gaich, J.Y. Chien, H. Fu, L.C. Glass, M.A. Deeg, W.L. Holland et al., The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18(3), 333–340 (2013)
V. Patel, R. Adya, J. Chen, M. Ramanjaneya, M.F. Bari, S.K. Bhudia et al., Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS One 9(2), E87102 (2014)
Acknowledgments
Yu Dan, Deshan Li, and Guiping Ren conceived and designed the experiments. Xianlong Ye, Qiang Wu, Shujie Li, et al. performed the experiments. Yu Dan, Deshan Li, and Guiping Ren analyzed the data. Yu Dan wrote the paper. Deshan Li and Guiping Ren revised the paper.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest.
Additional information
Both Deshan Li and Guiping Ren contributed equally to the design and supervision of the research for this article.
Rights and permissions
About this article
Cite this article
Yu, D., Ye, X., Wu, Q. et al. Insulin sensitizes FGF21 in glucose and lipid metabolisms via activating common AKT pathway. Endocrine 52, 527–540 (2016). https://doi.org/10.1007/s12020-015-0801-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-015-0801-9